

Date 03/02/2026  
Your Ref  
Our Ref 11008

Enquiries to Richard Mutch  
Extension 35687  
Direct Line 0131 465 5687  
[loth.freedomofinformation@nhs.scot](mailto:loth.freedomofinformation@nhs.scot)  
[richard.mutch@nhs.scot](mailto:richard.mutch@nhs.scot)

Dear

**FREEDOM OF INFORMATION – BLOOD CANCERS**

I write in response to your request for information in relation to blood cancers.

**Question:**

- Under the Freedom of Information Act of 2000, I would like to request the following information for your healthcare trust during the period 1st Jan2015 to 31st December 2025:
  1. Annual number of patients diagnosed with blood cancers per year overall, and by subtype:
    - Lymphomas (C81-86)
    - Malignant immunoproliferative diseases (C88)
    - Multiple myeloma and malignant plasma cell neoplasms (C90)
    - Leukaemia (C91-C95)
    - Unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues (C96)

**Answer:**

Year of incidence	Leukaemia (C91-C95)	Lymphomas (C81-C86)	Malignant immunoproliferative (C88)	Multiple myeloma/ Plasma cell (C90)	Unspecified lymphoid/ haematopoietic (C96)
2015	99	202	24	78	8
2016	120	189	22	88	5 or fewer
2017	104	196	13	73	8
2018	123	194	16	66	5 or fewer
2019	118	179	9	59	5 or fewer
2020	136	188	23	56	6
2021	126	178	18	70	5 or fewer
2022	114	194	22	76	6
2023	130	183	21	78	5 or fewer
2024	119	186	18	104	5 or fewer

Headquarters  
Mainpoint  
102 West Port  
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE  
Chief Executive Professor Caroline Hiscox  
*Lothian NHS Board is the common name of Lothian Health Board*



Notes:

This analysis uses SMR06 data from the period of 2015 to 2024. As 2024 is the latest year for which complete data is available, the 2025 period was excluded. The dataset includes patients registered with NHS Lothian who had an incidence date for a blood cancer diagnoses, matching the given ICD-10 codes, during this timeframe.

Question:

2. The number of blood cancer clinical trials available, including active trials that are recruiting and trials that are not actively recruiting.
3. Annual number of patients who were enrolled in interventional or observational clinical trials related to these blood cancers per year.
4. The scientific title, clinical trial registration number, phase (I/II/III/IV/other), opening and closing recruitment dates, number recruited at this trust, and location of each trial related to blood cancer.

Answer:

See enclosed spreadsheet.

Question:

5. The current number of dedicated research staff (e.g. research nurses, research practitioners, study coordinators etc.) assigned to haematological clinical trials.

Answer:

B7 Lead Research Nurse 0.8 WTE

B6 x 3 Senior Research Nurses 3.0 WTE

B6 Senior Data Manager 1.0 WTE

B5 x 3 Data Managers 3.0 WTE

Lab support team - help when required to manage blood and tissue samples - 1 x B7, 2 x B5, 1 x B3

Currently - 1 B6 Senior Research Nurse out to advert & funding for 1 x B5 Data Manager (not yet advertised)

Question:

6. If available, annual counts of invitations/offers made to eligible patients to consider trial participation.

Answer:

See enclosed spreadsheet.

I hope the information provided helps with your request.



If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at [www.itspublicknowledge.info/Appeal](http://www.itspublicknowledge.info/Appeal). If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director, Nursing**  
Cc: Chief Executive  
Enc.

IRAS Product Code	Study Title	Actual Start Date (Board)	Actual End Date (Board)	Product Status	Product Type	Trial Phase	Location Name	RDJ from Sponsor	Recruitment End	CITA Reference	ClinicalTrials.gov Reference	Extract	BRCTN	Protocol ID	Recruitment	
340897	Magnesium-16: An International Multicenter, Non-Interventional Post-Authorization Safety Study (PASS) to Evaluate the Effectiveness and Safety of Etanercept in Patients with Rheumatoid Arthritis (RA) and Psoriasis (PSS) Treated in Real-World Settings	15/09/2025	30/12/2028	Active	Commercial	N/A	Western General Hospital	06/10/2025						C1971816 - v2.0 - 04/06/2024	0	
101084	A Phase 3, multicenter, open-label, randomized, non-comparative two-arm study of Fingolimod (FING) monotherapy and combination (FING) monotherapy + adult patients with relapsing and remitting (RR) multiple sclerosis (MS) treated with fingolimod (FING) monotherapy	03/09/2025	31/01/2028	Active	Commercial	III	Western General Hospital	22/07/2025						5090301-178	0	
1008479	Optimizing Therapy in FLT3-Related Acute Myeloid Leukemia	17/07/2025	17/12/2030	Active	Eligible	II	Western General Hospital	11/05/2025						SPON11277-24	(5+) 2025	
1004049	A Phase 3, Multicenter, Randomized, Open-Label Study of ABW-003 Compared with Standard of Care (SOC) in Patients with Primary or Secondary Multiple Myeloma (MS, RRMM, IgG-Dominant Heavy Chain)	15/04/2025	30/1/2027	Active	Commercial	III	Western General Hospital	08/05/2025	2025-008665-15				M22-514	(5+) 2025		
1007177	A Phase 1 trial of a novel combination of a tyrosine kinase inhibitor and a CDK2 inhibitor in the treatment of acute myeloid leukemia	27/05/2025	31/12/2028	Active	Expanded Review	II	Western General Hospital	22/10/2025						UCI150882	(5+) 2025	
1006794	A Phase 1 Study to Assess Safety and Tolerability of REG-2022, an Anti-CD22 Anti-CD22 Chimeric Single-Domain Antibody, in Combination with Doxorubicin, in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma (A181831-1)	10/12/2024	04/08/2026	Active	Commercial	I	Western General Hospital	16/01/2025						REG2022-CMC-2019a181831w1	0	
1004191	Research outcomes of adult patients with Y84fs exposed relapsed or refractory multiple myeloma: Evidence from a multi-center retrospective study (MMP0561)	18/10/2024	18/08/2025	Completed	Commercial	NA	Western General Hospital							KT-45-687-0925	No recruitment recorded for this study as non consenting	
1010204	A Phase 2 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Doxorubicin in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (GCL35E-2)	02/09/2024	30/04/2028	In follow-up	Commercial	II	Western General Hospital	02/10/2024	19032025					CA873-1022	(5+) 2025	
1007256	A Phase 1/2C Open-Label, Dose Escalation, and Expansion Study of the Src-2 Inhibitor BGB-11417 in Patients With Metastatic Melanoma	21/05/2024	01/10/2029	Active	Commercial	II	Western General Hospital	20/06/2024						2021-00335-12	(5+) 2024, (5+) 2025	
1006044	A randomized trial to assess the role of prophylactic prophylaxis to prevent bacterial infection in children treated on the induction phase of the ALL Together1 treatment protocol	14/09/2024	14/06/2033	Active	Eligible	IIA	Royal Hospital for Sick Children and Young People Edinburgh	14/06/2024	201-00334-10		NCT04978989		SRCTN1198835	129028	(5+) 2024, (5+) 2025	
1005437	A Phase 1/2 Study of the Selective Androgen Receptor Modulator (SARM) Inhibitor NAL-055 in Patients with Advanced NSCLC and Other Solid Tumors (NAL055-1)	28/02/2024	28/02/2026	In follow-up	Commercial	II	Western General Hospital	24/07/2024	12022025	568430001001004	NCT03884626			NAL-055-01	(5+) 2024	
1007876	A Phase 3, Randomized, Multicenter, Controlled, Open-Label Study Comparing Bismuth-Based Regimens to Levofloxacin Maintenance Therapy after Completion of First-Line Treatment (NCT03748122) in Patients with Newly Diagnosed Multiple Myeloma (NMM) (JGCA-BE1-Maintenance)	06/02/2024	01/01/2033	Active	Commercial	III	Western General Hospital	13/02/2024						2022-001515-14-00	(5+) 2025	
1007320	An Open-Label, Randomized, Phase 3 Study of Lutetium-177 (177Lu)-DOTA-anti-CD226 Antibody (DOTA-anti-CD226) versus the Combination of Docetaxel, Prednisolone, and Doxorubicin (EPD), in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)	21/05/2024	04/03/2033	In follow-up	Commercial	III	Western General Hospital	04/01/2024	27632025					2022-001396-02	(5+) 2025	
1005070	Optimizing MDR1 as a resistance inducer in PCNSL: De novo induced induction treatment in newly diagnosed primary CNS lymphoma - a randomized phase 3 trial	05/10/2023	05/10/2027	Active	Eligible	III	Western General Hospital	05/03/2024						NCT04931398	2018-002115-96	SCC215P00001V.03 18.05.2022
1005865	A Phase 3 Randomized Study Comparing Tislelizumab in Combination with Docetaxel, Etoposide, and Levamisole (TLE-D) and Tislelizumab in Combination with Docetaxel, Etoposide, and Levamisole (TLE-D) versus Docetaxel, Etoposide, and Levamisole (DEL) in Patients with Newly Diagnosed Multiple Myeloma with or without high-risk or not treated for Autologous Stem Cell Transplantation	24/10/2023	16/05/2034	Active	Commercial	III	Western General Hospital	25/10/2023						2022-000909-28	6402797MMY3035	(5+) 2024, (5+) 2025
1006020	A Phase 2/3 Randomized, Open-Label, Parallel-Group Study of the Safety and Efficacy of the Novel CDK2 Inhibitor, BGB-11417, in Combination with Doxorubicin, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)	18/04/2023	31/03/2029	Active	Commercial	II	Western General Hospital	18/04/2023	30692025					AG546-C-002	(5+) 2025	
131548	Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)	18/10/2022	02/11/2023	Completed	Commercial	N/A	Western General Hospital	18/10/2022	22022024					R1979-CMC-2013	(5+) 2023	
131449	Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Systemic Therapy from Real-World Evidence (ORCA)	20/10/2022	04/11/2023	Completed	Commercial	N/A	Western General Hospital	10/10/2023	22022024					R1979-CMC-2000	(10) 2023	
304807	A Phase 1, Multi-center, open-label study to assess the safety, pharmacokinetics, and preliminary efficacy of an orally available small molecule, CC-9920, alone and in combination with rituximab in patients with relapsed or refractory non-Hodgkin Lymphoma (R/NHL)	29/09/2022	06/04/2028	In follow-up	Commercial	II	Western General Hospital	28/09/2022	17962025					CC-9920-NR1-001	(5+) 2025	
304832	A study to evaluate the safety and efficacy of a novel small molecule, CC-9920, in combination with rituximab in patients with relapsed or refractory non-Hodgkin Lymphoma (R/NHL)	21/07/2022	01/10/2023	Completed	NEP	N/A	Western General Hospital	22/07/2022						RF-304832 v1.0 (21.07.2022)	NEP - no recruitment recorded	
298475	A Phase 1b/2a/3a Randomized, Open-Label, Parallel-Group Study to Assess the Safety and Efficacy of the Novel CDK2 Inhibitor, BGB-11417, in Combination with Doxorubicin, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)	28/03/2022	31/10/2026	Active	Commercial	III	Western General Hospital	02/11/2022						NCT04244643	2019-00333-02	E2N-302 - V.6 - 15/05/2024
277035	Verapamil or Rituximab Chemotherapy for Treatment of Favourable Risk Acute Myeloid Leukemia: A Molecularly Guided Phase 2 Study	02/03/2022	31/05/2026	Active	Eligible	III	Western General Hospital	28/03/2022						2020-00273-24	RG_18-28217.v1.04_08.04.2020	(5+) 2022
280016	Correlation of baseline PET-CT parameters with subsequent radiographic dose response in multiple myeloma	01/03/2022	01/03/2022	Completed	Eligible	NA	Western General Hospital							000000	No recruitment recorded for this study as non consenting	
290110	A Phase 3 Open-Label, Randomized Study of LDX-305 versus Investigator's Choice of Bortezomib plus Velipristin or Doxorubicin plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)	27/09/2021	31/03/2028	In follow-up	Commercial	III	Western General Hospital	15/10/2021	30962025					NCT04866038	10X0-RTK-20200	(5+) 2022
272104	A treatment study protocol of the ALL Together Consortium for children and young adults (C-YA) ages 1-18 with newly diagnosed acute lymphoblastic leukaemia (ALL)	04/07/2021	31/03/2032	Active	Eligible	II	Western General Hospital	26/10/2021						NCT03911128	2018-001795-58	ALL Together V.0 (14/04/2023)
284888	A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Rituximab in Combination with Rituximab Versus Possible Therapy in Subjects with Relapsed/Refractory Multiple Myeloma	31/03/2021	03/11/2031	In follow-up	Commercial	III	Western General Hospital	15/04/2021	29042024					NCT04468884	2020-00557-27	M20-178
289472	Phase 1b/2a/3a Randomized, Open-Label, Parallel-Group Study to Assess the Safety, Pharmacokinetics, and Clinical Activity of NUC-7738, a Nucleoside Analog, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)	10/05/2021	30/06/2025	Completed	Commercial	III	Western General Hospital	10/05/2021	22042024					2020-00385-19	CL18-0487-003	(5+) 2022, (5+) 2023
273791	A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belinostat Monotherapy Compared to Placebo plus Low-Dose Doxorubicin (Belinostat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (RRMAB-3)	16/09/2020	01/07/2025	Completed	Commercial	III	Western General Hospital	17/09/2020	25032022					2018-00420-38	207N66	(5+) 2022, (7) 2023, (7) 2024, (5+) 2025
295860	An open-label Phase IIIa study to evaluate the safety and efficacy of CC-1447 in non-relapsed patients with advanced haematological malignancies	08/10/2020	01/09/2027	Active	Commercial	II	Western General Hospital	15/10/2020						2019-000164-15	CCS147-02 - V9.0 - 21/03/2025	(5+) 2021, (6) 2022, (10) 2023, (10) 2024, (9) 2025
294453	Firstly evaluated therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A Phase II trial to compare standard and fully optimized induction therapy with bortezomib, lenalidomide and doxorubicin (BCL) and maintenance lenalidomide (M) to lenalidomide plus bortezomib (LB)	09/09/2020	31/06/2027	In follow-up	Eligible	II	Western General Hospital	07/10/2020	04022024					NCT04702641	2018-00390-10	VS_24.3.23
253066	A two-part, Phase 1 (open-label, dose-escalation and expansion study) to assess the safety, pharmacokinetics and clinical activity of NUC-7738, a nucleoside analog, in patients with relapsed/Refractory Multiple Myeloma (RRMM)	13/03/2019	12/08/2028	Active	Commercial	I	Western General Hospital	31/07/2019						2018-003417-17	NuTri-701 - V3.6 - 04/07/2020	(5+) 2019, (5+) 2020, (5+) 2021, (5+) 2022, (5+) 2023, (5+) 2024, (5+) 2025
230113	A Phase 1/2 Open-Label, Randomized Study of LDX-305 versus Investigator's Choice of Bortezomib plus Velipristin or Doxorubicin plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)	28/07/2019	28/07/2021	Completed	Commercial	II	Western General Hospital	18/07/2019	02022020					2017-00148-19	NCR 30485-205 V.0.3 01.01.18	(5) 2017, (5) 2018
158193	A phase III study of belinostat (TLE) in combination with rituximab and doxorubicin for treatment of relapsed non-Hodgkin Lymphoma, with a focus on CLL17	11/04/2018	08/09/2022	Completed	Commercial	III	Western General Hospital	08/01/2019	13072022					2011-000033-36	LMRBT-37-01 - V1.1 - 19/02/2021	0
188181	Evaluation of outcomes in the management of classical Hodgkin lymphoma, with a focus on CD17	30/09/2018	30/09/2018	Completed	Eligible	NA	Western General Hospital	06/10/2018	13102018					151.00.03.18	(5) 2017, (5) 2018	
188116	Randomized, open label study of rituximab/lenalidomide vs rituximab/chemotherapy in elderly patients with advanced follicle cell lymphoma	29/09/2017	31/12/2036	Active	Eligible	III	Western General Hospital	01/12/2017	30962025					111 (26.08.2025)	(5) 2017, (5) 2019	
211526	Evaluation of CD17 as a diagnostic biomarker in classical Hodgkin lymphoma: ACCURATE Trial (MUSCIMA V3) - A phase II study to determine the role of rituximab as an adjuvant combination therapy in stage III/IV classical Hodgkin lymphoma (CHL) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed CHL	18/04/2017	31/05/2019	Completed	Eligible	NA	Royal Infirmary of Edinburgh at Little France 1	29/05/2017	07022019					Version 5 - 3rd August 2018	(5) 2017, (5) 2018, (10) 2019	
188054	Phase 1/2 Open-Label, Randomized Study of NUC-7738, a Nucleoside Analog, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)	10/07/2017	30/04/2027	In follow-up	Eligible	II	Western General Hospital	11/07/2017	31022022	181640233001	NCT03392169			2016-000605-55	10038966	V7.0 14.06.23
154668	Adults with acute myeloid leukemia or high-risk myelodysplastic syndrome (MDS)	31/12/2025	31/12/2025	Completed	Eligible	II	Western General Hospital	22/12/2015	29122025					2014-001195-50	78442023	SPON1336-14 V1.0 (28.02.2022)
137028	A single arm Phase III study of the safety and efficacy of personalized VIT-17CR therapy in patients with relapsed/refractory multiple myeloma (RRMM) with no first-line relapse (NFR) and no second relapse (NR2) and no third relapse (NR3)	26/10/2015	22/05/2018	Completed	Expanded Review	I	Western General Hospital	26/10/2015	22022018					D-00272-CT3014002 v4.0 24.6.16	0	
117123	A Phase 1/2 Randomized, Open-Label, Parallel-Group Study to Assess the Safety and Efficacy of the Novel CDK2 Inhibitor, BGB-11417, in Combination with Doxorubicin, in Patients with Relapsed/Refractory Multiple Myeloma	25/09/2015	11/07/2024	Completed	Commercial	II	Western General Hospital	28/09/2015	15052017					2014-0023115-10	D-00272-CT3014002 v4.0 24.6.16	No recruitment on RdA
418511168861341	With ongoing B-Cell lymphoma: downstream effects and impact on prognosis	15/02/2015	15/02/2015	Completed	Pilot	N/A	NEIS Leithan							CC-947-AM-007	(5+) 2015, (4) 2016, (5) 2017	
127379	ASL 101-A Trial for Older Patients with Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome	10/04/2015	31/12/2022	Completed	Eligible	II	Western General Hospital	10/04/2015	31/12/2022	21323042001	NCT02274718			2015-002795-21	3180779	V15.0 31.07.2022